Clinical Outcome of Acute Lymphocytic Leukemia with Concurrent MLL Gene Rearrangement and t (9; 22) in the Era of Tyrosine Kinase Inhibitors

2016 ◽  
Vol 16 ◽  
pp. S1
Author(s):  
Talha Badar ◽  
Hagop Kantarjian ◽  
Jorge Cortes ◽  
Elias Jabbour ◽  
Guillermo Garcia-Manero ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Acute Lymphocytic Leukemia ◽  
Gene Rearrangement ◽  
Kinase Inhibitors ◽  
Lymphocytic Leukemia ◽  
Mll Gene ◽  
Mll Gene Rearrangement

scholarly journals BCR-ABL1 gene rearrangement as a subclonal change in ETV6-RUNX1–positive B-cell acute lymphoblastic leukemia

2016 ◽  
Vol 1 (2) ◽  
pp. 132-138 ◽  
Author(s):  
Karen A. Dun ◽  
Rob Vanhaeften ◽  
Tracey J. Batt ◽  
Louise A. Riley ◽  
Giuseppe Diano ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Tyrosine Kinase ◽  
B Cell ◽  
Tyrosine Kinase Inhibitors ◽  
Gene Rearrangement ◽  
Kinase Inhibitors ◽  
Lymphoblastic Leukemia ◽  
Rare Occurrence ◽  
Key Points ◽  
Cell Acute Lymphoblastic Leukemia

Key Points BCR-ABL1 rearrangement as a subclonal change in ETV6-RUNX1–positive B-ALL is a rare occurrence not previously reported. The prognosis of this rare subclonal change has not been determined, yet inclusion of tyrosine kinase inhibitors in treatment is ubiquitous.

Myeloproliferative disorder with eosinophilia and ETV6–ABL gene rearrangement: Efficacy of second-generation tyrosine kinase inhibitors

2009 ◽  
Vol 33 (8) ◽  
pp. 1144-1146 ◽  
Author(s):  
Ranveer Nand ◽  
Christine Bryke ◽  
Steven H. Kroft ◽  
Ajit Divgi ◽  
Christopher Bredeson ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Gene Rearrangement ◽  
Second Generation ◽  
Kinase Inhibitors ◽  
Myeloproliferative Disorder

Resistance to Bruton's Tyrosine Kinase Inhibitors: The Achilles Heel of Their Success Story in Lymphoid Malignancies

Blood ◽  
2021 ◽  
Author(s):  
Deborah M. Stephens ◽  
John C Byrd
Keyword(s):  
Tyrosine Kinase ◽  
B Cell ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors ◽  
Lymphocytic Leukemia ◽  
Treatment Modalities ◽  
Bruton’S Tyrosine Kinase ◽  
B Cell Malignancies ◽  
Bruton's Tyrosine Kinase ◽  
Resistant Disease

Bruton's tyrosine kinase inhibitors (BTKi) have significantly changed the treatment landscape for patients with B-cell malignancies including chronic lymphocytic leukemia (CLL), Waldenstrom's macroglobulinemia (WM), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL). Unfortunately, patients with BTKi resistant disease have shortened survival. Clinical and molecular risk factors, such as number of prior therapies and presence of TP53 mutations, can be used to predict patients at the highest risk of developing BTKi resistance. Many mechanisms of BTKi resistance have been reported with mutations in BTK and phospholipase C g 2 supported with the most data. The introduction of venetoclax has lengthened the survival of patients with BTKi resistant disease. Ongoing clinical trials with promising treatment modalities such as next-generation BTKi and chimeric antigen receptor T-cell therapy have reported promising efficacy in patients with BTKi resistant disease. Continued research focusing on resistance mechanisms and methods of how to circumvent resistance is needed to further prolong the survival of patients with BTKi resistant B-cell malignancies.

Tyrosine Kinase Inhibitors in Lymphocytic Leukemia

2021 ◽  
pp. 225-238
Author(s):  
Sandeep Arora ◽  
Tapan Behl ◽  
Sukhbir Singh ◽  
Neelam Sharma ◽  
Nidhi Garg
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors ◽  
Lymphocytic Leukemia
Sign in / Sign up

Export Citation Format

Share Document